American Heart Association – 2020 Baris Gencer – Efficacy of Lowering Low-Density Lipoprotein Cholesterol in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Daniel Marcusa – Relationship Between Baseline LDL-C and %LDL-C Reduction with Evolocumab in the FOURIER Trial Kazuma Oyama – Reduction with Evolocumab in Complex Coronary Revascularization: Insights from the FOURIER Trial Parth Patel – A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease Anthony Carnicelli – In-Hospital vs Out-of-Hospital Cardiac Arrest in Patients Presenting to Cardiac Intensive Care Units From the Critical Care Cardiology Trials Network (CCCTN) David Berg – A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients with T2DM in DECLARE-TIMI 58 David Berg – Biomarker-Based Heart Failure Risk Stratification in Patients with Atherosclerotic Cardiovascular Disease: Observations From HPS3/TIMI-55 REVEAL David Berg – Development of A Novel Biomarker-Based Risk Score for Heart Failure in Patients with Diabetes Kazuma Oyama – Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients with T2DM in the DECLARE-TIMI 58 Trial Nicholas Marston – Cardiovascular Outcomes in Patients with Established Atherosclerosis and LDLR Loss of Function: Results from the FOURIER Trial Nicholas Marston – Combining High-Sensitivity Troponin with the AHAACC Cholesterol Guidelines To Guide Evolocumab Therapy Remo Furtado – Effects of Evolocumab in Patients with Prior Percutaneous Coronary Intervention: An Analysis from the FOURIER Trial Thomas Zelniker – Relationship between cardiac biomarkers and major adverse cardiovascular events in DECLARE-TIMI 58 Share this:TwitterFacebookLike this:Like Loading...
